Search results for "diabetes mellitu"

showing 10 items of 2088 documents

Noncoding RNAs in Critical Limb Ischemia

2020

Peripheral artery disease, caused by chronic arterial occlusion of the lower extremities, affects over 200 million people worldwide. Peripheral artery disease can progress into critical limb ischemia (CLI), its more severe manifestation, which is associated with higher risk of limb amputation and cardiovascular death. Aiming to improve tissue perfusion, therapeutic angiogenesis held promise to improve ischemic limbs using delivery of growth factors but has not successfully translated into benefits for patients. Moreover, accumulating studies suggest that impaired downstream signaling of these growth factors (or angiogenic resistance) may significantly contribute to CLI, particularly under h…

0301 basic medicineRNA UntranslatedAngiogenesisCritical IllnessNeovascularization PhysiologicDisease030204 cardiovascular system & hematologyBioinformaticsArticlePeripheral Arterial Disease03 medical and health sciences0302 clinical medicineIschemiaRisk FactorsmicroRNADiabetes MellitusAnimalsHumansMedicineTherapeutic angiogenesisProgenitor cellHypoxiaInflammationbusiness.industryStem CellsHemodynamicsCritical limb ischemiaHypoxia (medical)Prognosisbody regions030104 developmental biologyGene Expression RegulationRegional Blood FlowArteriogenesismedicine.symptomCardiology and Cardiovascular MedicinebusinessSignal TransductionArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Extrahepatic Manifestations of Chronic Viral C Hepatitis.

2020

Hepatits C virus (HCV) infection has been largely associated with extrahepatic comorbidities such as diseases related to dysregulation of the immune system, neuropsychiatric disorders, and cardiometabolic alterations. These clinical consequences, together with experimental evidence, suggest a potential (in)direct effect of HCV, contributing to the pathogenesis of these diseases. Various studies have reported a positive effect of viral eradication on occurrence and outcomes of extrahepatic diseases. These observations and the availability of safe and effective direct antiviral agents further underline the need to search for virological eradication in all infected individuals independent of t…

0301 basic medicineRiskSustained Virologic Responsemacromolecular substancesAntiviral AgentsVirusPathogenesisCohort Studies03 medical and health sciencesLiver disease0302 clinical medicineImmune systemDiabetes mellitusmedicineHepatitisbusiness.industryLymphoma Non-HodgkinMental DisordersGastroenterologyHepatitis C Chronicmedicine.diseaseCardiovascular disease Diabetes Extrahepatic complications HCV Immune-related disorders Kidney disease030104 developmental biologyCross-Sectional StudiesCryoglobulinemiaCardiovascular DiseasesImmunology030211 gastroenterology & hepatologybusinessKidney diseaseGastroenterology clinics of North America
researchProduct

Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?

2018

Anti-PCSK9 (proprotein convertase subtilisin kexin 9) monoclonal antibodies (Mab) are novel, potent lipid-lowering drugs. They demonstrated to improve the lipid profile in high cardiovascular risk patients. Anti-PCSK9 Mab inhibit the targeted low-density lipoprotein (LDL)-receptor degradation induced by PCSK9 protein and are able to reduce LDL cholesterol (LDL-C) levels on top of conventional lipid-lowering therapy. Though these drugs proved to be very safe in the short-term, little is known about the possible long-term effects, due to the short period of their marketing. The genetic low cholesterol syndromes (LCS) represent the natural models of the lipid-lowering anti-PCSK9 therapy, and a…

0301 basic medicineSerine Proteinase InhibitorsTime FactorsPhysiologymedicine.drug_class030204 cardiovascular system & hematologyPharmacologyMonoclonal antibodyRisk Assessment03 medical and health sciencesPCSK9 Genechemistry.chemical_compound0302 clinical medicineRisk FactorsPhysiology (medical)Diabetes mellitusmedicineAnimalsHumansDyslipidemiasmedicine.diagnostic_testbusiness.industryCholesterolPCSK9Anticholesteremic AgentsPCSK9 InhibitorsAntibodies MonoclonalCholesterol LDLmedicine.diseaseFatty LiverHypocholesterolemia030104 developmental biologyTreatment OutcomechemistryDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular MedicineLipid profilebusinessCognition DisordersBiomarkersLipoproteinCardiovascular research
researchProduct

Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6…

2019

The objective was to evaluate the effects of 6 months of supplementation with Altilix&reg

0301 basic medicineSettore MED/09 - Medicina Internacynaragenetic structuresPlacebo-controlled study030204 cardiovascular system & hematologySettore BIO/09 - FisiologiaGastroenterology0302 clinical medicineDiabetes mellitusimmune system diseasescardiovascular diseasehemic and lymphatic diseasesBrachial arteryLuteolinNutrition and Dieteticsdiabetes mellituFatty liverhemic and immune systemsDietary supplementsMetabolic syndromeCardiovascular diseasesLivertype 2diabetes mellitusChlorogenic Acidlcsh:Nutrition. Foods and food supplymedicine.medical_specialtyWaistlcsh:TX341-641chemical and pharmacologic phenomenaCynaraPlacebometabolic syndromedietary supplements03 medical and health sciencesDouble-Blind MethodInternal medicineDiabetes mellitusmedicine.arterymedicinebusiness.industrynon-alcoholic fatty liver diseasemedicine.diseasecardiovascular diseases030104 developmental biologydietary supplementSteatosisMetabolic syndromebusinessFood ScienceNon-alcoholic fatty liver disease
researchProduct

A Systematic Study of Dysregulated MicroRNA in Type 2 Diabetes Mellitus

2017

MicroRNAs (miRNAs) are small noncoding RNAs that modulate the cellular transcriptome at the post-transcriptional level. miRNA plays important roles in different disease manifestation, including type 2 diabetes mellitus (T2DM). Many studies have characterized the changes of miRNAs in T2DM, a complex systematic disease; however, few studies have integrated these findings and explored the functional effects of the dysregulated miRNAs identified. To investigate the involvement of miRNAs in T2DM, we obtained and analyzed all relevant studies published prior to 18 October 2016 from various literature databases. From 59 independent studies that met the inclusion criteria, we identified 158 dysregu…

0301 basic medicineSystematic surveytype 2 diabetes mellitussystematic study030209 endocrinology & metabolismDiseaseBioinformaticsCatalysisArticleInorganic ChemistryTranscriptomelcsh:Chemistry03 medical and health sciences0302 clinical medicineDiabetes mellitusmiRNA-mRNA interaction networkmicroRNAmedicineHumansGene Regulatory NetworksRNA MessengerPhysical and Theoretical Chemistry10. No inequalityMolecular Biologylcsh:QH301-705.5SpectroscopyAdipocytokine Signaling PathwaymicroRNA; type 2 diabetes mellitus; miRNA-mRNA interaction network; systematic studymicroRNAbusiness.industryGene Expression ProfilingOrganic ChemistryType 2 Diabetes MellitusGeneral Medicinemedicine.diseaseComputer Science ApplicationsMicroRNAs030104 developmental biologyDiabetes Mellitus Type 2Gene Expression Regulationlcsh:Biology (General)lcsh:QD1-999Organ SpecificityRNA InterferenceDisease manifestationbusinessTranscriptomeSignal TransductionInternational Journal of Molecular Sciences
researchProduct

The influence of meal frequency and timing on health in humans: The role of fasting

2019

The influence of meal frequency and timing on health and disease has been a topic of interest for many years. While epidemiological evidence indicates an association between higher meal frequencies and lower disease risk, experimental trials have shown conflicting results. Furthermore, recent prospective research has demonstrated a significant increase in disease risk with a high meal frequency (≥6 meals/day) as compared to a low meal frequency (1–2 meals/day). Apart from meal frequency and timing we also have to consider breakfast consumption and the distribution of daily energy intake, caloric restriction, and night-time eating. A central role in this complex scenario is playe…

0301 basic medicineTime FactorsTime FactorCircadian clockPhysiology030209 endocrinology & metabolismlcsh:TX341-641ReviewDiseaseGut floraDiabete03 medical and health sciences0302 clinical medicineDiabetes mellitusTime-restricted feedingmedicineHumanscardiovascular health; diabetes; fasting; meal frequency; meal timing; obesity; time-restricted feedingCircadian rhythmObesityMealsMeal030109 nutrition & dieteticsNutrition and Dieteticsbiologydiabetesbusiness.industryMeal timingdigestive oral and skin physiologyFastingFeeding Behaviorbiology.organism_classificationmedicine.diseaseObesityCardiovascular healthMeal frequencyProspective researchbusinesslcsh:Nutrition. Foods and food supplyFood ScienceHuman
researchProduct

Disease-Specific and Common HLA and Non-HLA Genetic Markers in Susceptibility to Rheumatoid Arthritis, Type 1 Diabetes Mellitus and Multiple Sclerosis

2016

Autoimmune diseases cause numerous health and social problems throughout the world. The common spectrum of autoimmune diseases affect the majority of tissues within the body, including pancreatic beta cells in type 1 diabetes (T1DM), myelin surrounding nerve axons in Multiple sclerosis (MS) and synovial joint antigens in Rheumatoid Arthritis (RA). The diseases are likely caused by a complex interaction between multiple HLA- and non- HLA related genes and environmental factors. The well documented co-clustering of autoimmune diseases within families and individuals, together with apparent sharing of number risk genes between the diseases suggests at least some common mechanisms of autoimmune…

0301 basic medicineType 1 diabetesbusiness.industryMultiple sclerosisGenetic enhancementHuman leukocyte antigenmedicine.disease03 medical and health sciencesMyelin030104 developmental biologymedicine.anatomical_structureAntigenRheumatoid arthritisDiabetes mellitusImmunologymedicinebusinessJournal of Molecular and Genetic Medicine
researchProduct

Enzymatic Activity of HPGD in Treg Cells Suppresses Tconv Cells to Maintain Adipose Tissue Homeostasis and Prevent Metabolic Dysfunction.

2019

Summary Regulatory T cells (Treg cells) are important for preventing autoimmunity and maintaining tissue homeostasis, but whether Treg cells can adopt tissue- or immune-context-specific suppressive mechanisms is unclear. Here, we found that the enzyme hydroxyprostaglandin dehydrogenase (HPGD), which catabolizes prostaglandin E2 (PGE2) into the metabolite 15-keto PGE2, was highly expressed in Treg cells, particularly those in visceral adipose tissue (VAT). Nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ)-induced HPGD expression in VAT Treg cells, and consequential Treg-cell-mediated generation of 15-keto PGE2 suppressed conventional T cell activation and proliferation. C…

0301 basic medicineanalogs & derivatives [Dinoprostone]Malemetabolism [Diabetes Mellitus Type 2]Adipose tissueLymphocyte Activation15-ketoprostaglandin E2T-Lymphocytes RegulatoryJurkat cellsJurkat CellsMice0302 clinical medicineimmunology [Lymphocyte Activation]genetics [Insulin Resistance]STAT5 Transcription FactorHomeostasisImmunology and AllergyTissue homeostasisgenetics [Hydroxyprostaglandin Dehydrogenases]Mice Knockoutcytology [Intra-Abdominal Fat]enzymology [T-Lymphocytes Regulatory]FOXP3hemic and immune systems3T3 CellsCell biologyInfectious Diseases030220 oncology & carcinogenesisHydroxyprostaglandin Dehydrogenasesmedicine.symptomimmunology [T-Lymphocytes Regulatory]metabolism [STAT5 Transcription Factor]Immunologymetabolism [Dinoprostone]chemical and pharmacologic phenomenaInflammationIntra-Abdominal FatBiologyDinoprostoneCell Line03 medical and health sciencesmetabolism [Hydroxyprostaglandin Dehydrogenases]immunology [Homeostasis]medicineAnimalsHumansddc:610immunology [Intra-Abdominal Fat]HEK 293 cells030104 developmental biologyHEK293 CellsDiabetes Mellitus Type 2Cell cultureInsulin ResistanceHomeostasis
researchProduct

Liraglutide Ameliorates Erectile Dysfunction via Regulating Oxidative Stress, the RhoA/ROCK Pathway and Autophagy in Diabetes Mellitus

2020

Background Erectile dysfunction (ED) occurs more frequently and causes a worse response to the first-line therapies in diabetics compared with nondiabetic men. Corpus cavernosum vascular dysfunction plays a pivotal role in the occurrence of diabetes mellitus ED (DMED). The aim of this study was to investigate the protective effects of glucagon-like peptide-1 (GLP-1) analog liraglutide on ED and explore the underlying mechanisms in vivo and in vitro. Methods Type 1 diabetes was induced in rats by streptozotocin, and the apomorphine test was for screening the DMED model in diabetic rats. Then they were randomly treated with subcutaneous injections of liraglutide (0.3 mg/kg/12 h) for 4 weeks. …

0301 basic medicineautophagyRHOAerectile dysfunctionPharmacologymedicine.disease_cause03 medical and health sciences0302 clinical medicineDiabetes mellitusmedicineoxidative stressPharmacology (medical)PharmacologyliraglutideType 1 diabetesbiologybusiness.industryLiraglutidelcsh:RM1-950Autophagymedicine.diseaseStreptozotocinlcsh:Therapeutics. Pharmacology030104 developmental biologyErectile dysfunction030220 oncology & carcinogenesisdiabetes mellitusbiology.proteinbusinessOxidative stressmedicine.drugFrontiers in Pharmacology
researchProduct

Can we prevent and modify cardiometabolic disorders by controlling HCV infection?

2017

HCV infection has an estimated global prevalence of 1.0%, corresponding to roughly 71.1 million of infected individuals in 2015, with major geographical heterogeneity.1 Due to the large burden of infected individuals in the general population, the likelihood of co-occurrence of chronic HCV infection and common comorbidities is substantial regardless of causal linkages. Population-based studies show a higher overall mortality, both for liver-related and unrelated causes in HCV infected subjects compared with those uninfected, and cross-sectional and cohort studies identify HCV as an independent risk factor for extrahepatic manifestations.2 These issues are summarised in two meta-analyses rep…

0301 basic medicineeducation.field_of_studybusiness.industryPopulationGastroenterologyHepatitis CType 2 diabetesDiseasemedicine.diseaseHepatitis C03 medical and health sciences030104 developmental biology0302 clinical medicineDiabetes mellitusCardiovascular DiseaseImmunologyMedicine030211 gastroenterology & hepatologyPorphyria cutanea tardaRisk factorbusinesseducationCohort study
researchProduct